Chimera Constructs
|
Slide Agglutination
|
Western blots
|
---|
 |  |  | LPS | Membrane |
---|
 | MASF Ic | Type IV | MASF Ic | Type IV | Anti-PhoA |
---|
| +ve | -ve | +ve | -ve | +ve |
| -ve | +ve | -ve | +ve | +ve |
| -ve | -ve | -ve | -ve | -ve |
| -ve | -ve | -ve | -ve | +ve |
| -ve | -ve | -ve | -ve | +ve |
| -ve | -ve | -ve | -ve | +ve |
- Points of fusion: a) GtrIc-GtrIV loop No.2-GtrIc chimera:GtrIc-F31/GtrIV-N27, GtrIV-Y68/GtrIc-V100, b) GtrIV-GtrIc loop No.2-GtrIV chimera: GtrIV-M26/GtrIc-H32, GtrIc-N99/GtrIV-S71, c) GtrIc-GtrIV loop No.6-GtrIc chimera: GtrIc-P382/GtrIV-T231, GtrIV-K351/GtrIc-V495, d) GtrIV-GtrIc loop No.10-GtrIV chimera: GtrIV-S229/GtrIc-T231, GtrIc-V381/GtrIV-D352. To test for GtrIc function, the chimera constructs were transformed in to SFL1416 (Serotype 1a) to test for serotype conversion to serotype 1c using MASF Ic. As for GtrIV function, conversion to serotype 4a was tested by using Type IV antisera against constructs that were transformed into SFL1616 (serotype Y). All membrane protein westerns were carried using anti-alkaline phosphatse antibodies.